CASP2

Across TCGA pan-cancer cohorts, CASP2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CASP2 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CASP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CASP2 expression acts as an unfavorable survival marker.

PDAC, LUAD, and GBM are the cancer types where CASP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.361	0.647	.005	18	view →
LUAD	OS	Median	II,III,IV	0.442	0.899	.015	9	view →
GBM	OS	Tertile	All	0.775	0.854	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CASP2–PDAC (OS)

Open the PDAC breakdown →